Alterity Therapeutics (ATH) H2 2024 earnings summary

Executive summary

• Achieved key milestones in clinical development for lead asset ATH434, targeting Multiple System Atrophy (MSA), with two Phase 2 trials ongoing and positive interim data reported in advanced MSA patients.

• Expanded intellectual property portfolio, including new patents covering over 150 novel compounds for neurodegenerative diseases.

• Raised A$10.1 million in equity during the year to support R&D activities; cash and cash equivalents at year-end were A$12.6 million.

• Management and auditors highlighted material uncertainty regarding the company's ability to continue as a going concern due to recurring losses and need for additional capital.

Financial highlights

• Net loss for the year ended June 30, 2024 was A$19.1 million, compared to A$13.8 million in 2023.

• Research and development expenses increased 41.3% to A$18.6 million, reflecting expanded clinical activity.

• General and administrative expenses decreased 5.8% to A$4.8 million.

• Interest income rose to A$268,419, and R&D tax incentive income was A$4.0 million.

• Cash used in operating activities was A$12.6 million; cash and cash equivalents at year-end were A$12.6 million.

Outlook and guidance

• Topline data from the ATH434-201 Phase 2 trial in early-stage MSA expected in January 2025; topline data from the ATH434-202 trial in advanced MSA expected in the first half of 2025.

• Company intends to raise new equity funding within six months of year-end to continue R&D programs.

• Ongoing focus on advancing ATH434 and expanding the pipeline of neurodegenerative disease candidates.